ClinicalTrials.gg
Enrolling by invitationNCT05122325Updated Feb 19, 2025

Treatment for Sexual Dysfunction in Women with Spinal Cord Injury

An interventional study of Transcutaneous tibial nerve stimulation TENS® EMS NMS60 device and Genital vibration with Ferticare 2.0® vibrator in Spinal Cord Injuries, sponsored by Cristina Lirio. Enrolling by invitation at 1 site in Spain. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by Cristina Lirio · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Spinal Cord Injuries with a site in Spain — 11 open to participants now, 13 under way, 1 of them phase 3. Spinal Cord Injuries · Spain.

Planned enrollment
16th of 55
54 · median 30
Started
2026
with 4 others
No phase
34 of 59
8 open now
Primary completion
2026-10
later than 6 of 12 live
Registered
35th of 59
by date

Among the 59 studies in Spinal Cord Injuries with a site in Spain, this one is the 16th largest by planned enrollment of the 55 interventional ones that give a count, is one of 5 that started in 2026, is one of 34 with no phase, reaches primary completion later than 6 of the 12 other live ones, and was the 35th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

11 of the 59 studies in Spinal Cord Injuries with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 60 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Spinal Cord Injuries with a site in Spain, or all of them as a file.
02

Study summary

Women with spinal cord injury frequently experience sexual dysfunction such as disturbances during arousal and an increased time to orgasm. However, little evidence has been found on its therapeutic approach and low adherence. To verify the effectiveness of two interventions: the application of genital vibration and transcutaneous stimulation of the tibial nerve.

This is a randomized clinical trial. 54 women will be recruited who suffer from sexual dysfunction.

Read the detailed description

The allocation will be randomly assign to the three groups: an intervention group 1 transcutaneous electrostimulation of tibial nerve (n = 18), an intervention group 2 genital vibration (n = "18) and a control group (n = 18). The treatment time will be 12 weeks. Treatment adherence, as well as treatment effectiveness, will be evaluated through the Female Sexual Function Index, the "Sexual Quality of Life-Female" questionnaire, quantitative sensory tests and the improvement reported by the patient in arousal and orgasm. Evaluations will be carried out before treatment, at the end of the treatment, and at 3 and 6 months after the end of treatment.

03

Conditions studied

  • Spinal Cord Injuries

Keywords

  • Spinal cord injuries
  • Women
  • Pelvic floor disorders
  • Sexuality
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with incomplete spinal cord injury B, C or D (with preservation of the sacral arch and sensitive assessment of the lower dermatomes not absent, paying special attention to the sensitivity of the genital area) level below T6.
  • between 18-60 years
  • hormonal analysis. Participants do not present menopausal values of the hormone FSH (follicle stimulating hormone ) (31- 134 U / L)
  • present some type of sexual disorder secondary to spinal cord injury with at least 12 months of evolution
  • from Spain
  • willing to attend the evaluation and treatment center
  • seeking to improve in the sexual area.

Exclusion criteria

Exclusion Criteria:

  • women with active pregnancy
  • present pre-existing pathologies in the genital area
  • genital malformation, previous neurosurgery that affects the genital response capacity
  • sexual disorders before the injury
  • pressure ulcers, serious medical illness or any type of pathology in which the use of sick leave is frequency
  • psychiatric disorder, narcotic dependence, use of specific serotonin reuptake inhibitors, antipsychotics or other drugs that affect sexual response.
  • does not sign the .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Intervention group 1: Transcutaneous tibial nerve stimulation (TTNS)

    Transcutaneous application of low frequency electrical current over the tibial nerve TENS® EMS NMS60 for a 30 minutes session, twice a week. Placing a small electrode 3 fingers up to the internal malleolus and 1 cm posterior (adjusting its placement with a point finder or testing with low frequencies of 2-3 Hz). A large electrode placed in the calcaneus.

    Device: Transcutaneous tibial nerve stimulation TENS® EMS NMS60 device

  • Experimental
    Intervention group 2: Genital vibration

    Women will be instructed in the use of the Ferticare 2.0® vibrator with a frequency of 70 Hz, amplitude of 1.5 mm. It will be recommended to gradually increase its use over time, with a limit of 30 minutes a day.

    Device: Genital vibration with Ferticare 2.0® vibrator

  • Sham comparator
    Control group

    A sham of TTNS intervention with the device turned off, twice a week.

    Device: TENS® EMS NMS60 device_sham intervention

Interventions

  • DeviceTranscutaneous tibial nerve stimulation TENS® EMS NMS60 device

    Stimulation sessions with a TENS® EMS NMS60 device. These will be carried out for 30 minutes, once a week at 10 Hz, with a pulse width of 200 μs and an intensity between 0 and 100 mA, which will be individually adjusted to each participant. Inicially, frequency between 2-3 Hz, so that when the current passes, a contraction-relaxation will cause the first toe movement visually evident (excitomotor threshold). Once verified, the frequency is raised to what has been established between 10Hz and there the intensity is increased without having to now reach the excitomotor threshold, as long as the physiotherapist notice it is enough (it must be tolerable).

    Also known as: TTNS

  • DeviceGenital vibration with Ferticare 2.0® vibrator

    Women will be instructed in the use of the Ferticare 2.0® vibrator. Initially, a practice will be carried out , indicating that the frequency of use will be 70 Hz with an amplitude of 1.5 mm. It will be recommended to gradually increase its use over time, with a limit of 30 minutes a day.

    Also known as: vibration

  • DeviceTENS® EMS NMS60 device_sham intervention

    Sham of TTNS intervention with Stimulation sessions with a TENS® EMS NMS60 device. These will be carried out for 30 minutes, once a week. Inicially, frequency between 2-3 Hz, so that when the current passes, a contraction-relaxation will cause the first toe movement visually evident (excitomotor threshold). Once verified, the intensity is decreased to lower the sensitive threshold of treatment.

    Also known as: Control

06

What researchers measure

Primary outcomes

  1. The "Index of female sexual function (IFSF)"

    This questionnaire showed validity, internal consistency in all its domains, specifically Cronbach's Alpha 0.745 in arousal and 0.753 in orgasm and test-retest reliability of ICC 0.96. This questionnaire consists of 19 questions and is grouped into six domains. The score for each domain is multiplied by a factor and the final result is the arithmetic sum of the domains. The higher the score, the better sexuality.

    Time frame: 5 minutes

  2. Sexual Quality of Life-Female (SQOL-F)

    SQOL-F showed good validity and reliability. The questionnaire was developed to measure the impact of sexual disorders on quality of life. This questionnaire consists of 18 questions with a response scale of 6 options. The quality of sexual life will be considered poor if the score is between 18-51, moderate between 51-84 and good if it is greater than 84.

    Time frame: 5 minutes

07

Study locations

1 site
  • Cristina Lirio-Romero
    Toledo, 45001, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Oct 2026, 4 months later.

Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 4 months is below that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2021
First posted
Nov 16, 2021
StartEst.
Jun 2026
Primary completionEst.
Oct 2026
CompletionEst.
Jan 2027
Last update
Feb 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05122325
Lead sponsor
Cristina Lirio
Responsible party
Cristina Lirio (Director, University of Castilla-La Mancha) — Sponsor-investigator
First posted
Nov 16, 2021
Start date
Jun 2026 (estimated)
Primary completion
Oct 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Feb 19, 2025

Study contacts

Cristina Lirio-Romero, PhD
study director · University of Castilla-La Mancha

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion